


CU-CPT9b

Cat. No.:	HY-112051		
CAS No.:	2162962-69-6		
Molecular Formula:	C ₁₆ H ₁₃ NO ₂		
Molecular Weight:	251.28		
Target:	Toll-like Receptor (TLR)		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (331.62 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		3.9796 mL	19.8981 mL	39.7962 mL
	5 mM		0.7959 mL	3.9796 mL	7.9592 mL	
	10 mM		0.3980 mL	1.9898 mL	3.9796 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	CU-CPT9b is a specific TLR8 antagonist, with an IC ₅₀ of 0.7 nM. CU-CPT9b shows high binding affinity towards TLR8 with a K _d of 21 nM ^[1] .	
IC₅₀ & Target	TLR8 0.7 nM (IC ₅₀)	TLR8 21 nM (K _d)
In Vitro	CU-CPT9b is a specific TLR8 antagonist, with an IC ₅₀ of 0.7±0.2 nM. ITC experiments have confirmed the strong binding of	

CU-CPT9b with a K_d of 21 nM. It is shown that CU-CPT-9b binds to the inactive TLR8 dimer in a similar way to CU-CPT8m. CU-CPT9b utilizes hydrogen bonds with G351 and V520*, which are conserved among TLR8/antagonist structures. Additionally, CU-CPT9b forms water-mediated contacts with S516* and Q519*, which are not observed in TLR8/CU-CPT8m structure, suggesting that the enhanced potency of CU-CPT9b derives from the new interactions with these polar residues. The orientation of Y567* also changes to facilitate van der Waals interactions with CU-CPT9b as compared to TLR8/CU-CPT8m^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- BMC Med. 2021 Oct 15;19(1):247.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Zhang S, et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol. 2018 Jan;14(1):58-64.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA